biotechnologyArtiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advanceViaNews Editorial Team•Mar 7, 2026
AnalysisFour Immunotherapy Companies Race Toward 2026 Launches as Next-Generation Cancer Treatments Near MarketViaNews Editorial Team•Feb 15, 2026
